Researchers at St Vincent’s Institute of Medical Research (SVI) in Melbourne are leading a world-first clinical trial to test the effectiveness of the drug Baricitinib to stop the immune system from destroying the insulin-producing cells in the pancreas in people with newly diagnosed type 1 diabetes. Baricitinib is currently used as a treatment for rheumatoid arthritis.
If successful, the use of baricitinib may help people living with type 1 diabetes to continue natural insulin production for longer after diagnosis, delaying the commencement of insulin treatment.
The two-year BANDIT (baricitinib in new-onset type 1 diabetes) trial is funded by the Juvenile Diabetes Research Foundation (JDRF) and will run at three sites in Melbourne: The Royal Melbourne Hospital, The Royal Children’s Hospital and St Vincent’s Hospital Melbourne.
People between 12-30 years old who have recently been diagnosed with type 1 diabetes are being sought to take part in the two-year trial. Participants do not have to be patients of these hospitals and would continue to see their usual doctor during and after the trial, as necessary.
For more information about the clinical trial and what participation involves, contact the team at St. Vincent’s Institute in Melbourne here.